195 related articles for article (PubMed ID: 19515085)
1. Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.
Katakowski M; Jiang F; Zheng X; Gutierrez JA; Szalad A; Chopp M
Cancer Sci; 2009 Sep; 100(9):1597-604. PubMed ID: 19515085
[TBL] [Abstract][Full Text] [Related]
2. ADAM17 promotes glioma cell malignant phenotype.
Zheng X; Jiang F; Katakowski M; Lu Y; Chopp M
Mol Carcinog; 2012 Feb; 51(2):150-64. PubMed ID: 21480393
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
[TBL] [Abstract][Full Text] [Related]
4. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
Wang XJ; Feng CW; Li M
Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
[TBL] [Abstract][Full Text] [Related]
5. MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells.
Lu Y; Chopp M; Zheng X; Katakowski M; Buller B; Jiang F
Oncol Rep; 2013 Jan; 29(1):67-72. PubMed ID: 23076445
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion.
Zheng X; Jiang F; Katakowski M; Zhang X; Jiang H; Zhang ZG; Chopp M
Cancer Lett; 2008 Jul; 265(2):177-87. PubMed ID: 18358600
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
Zheng X; Jiang F; Katakowski M; Kalkanis SN; Hong X; Zhang X; Zhang ZG; Yang H; Chopp M
Cancer Sci; 2007 May; 98(5):674-84. PubMed ID: 17355261
[TBL] [Abstract][Full Text] [Related]
8. Effects of tetrandrine on glioma cell malignant phenotype via inhibition of ADAM17.
Wu Z; Wang G; Xu S; Li Y; Tian Y; Niu H; Yuan F; Zhou F; Hao Z; Zheng Y; Li Q; Wang J
Tumour Biol; 2014 Mar; 35(3):2205-10. PubMed ID: 24185966
[TBL] [Abstract][Full Text] [Related]
9. ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway.
Lin P; Sun X; Feng T; Zou H; Jiang Y; Liu Z; Zhao D; Yu X
Mol Cell Biochem; 2012 Jan; 359(1-2):235-43. PubMed ID: 21837402
[TBL] [Abstract][Full Text] [Related]
10. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
Zheng X; Jiang F; Katakowski M; Zhang ZG; Lu QE; Chopp M
Cancer Biol Ther; 2009 Jun; 8(11):1045-54. PubMed ID: 19395875
[TBL] [Abstract][Full Text] [Related]
11. ERK1/2 mediate wounding- and G-protein-coupled receptor ligands-induced EGFR activation via regulating ADAM17 and HB-EGF shedding.
Yin J; Yu FS
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):132-9. PubMed ID: 18658095
[TBL] [Abstract][Full Text] [Related]
12. TNF-α-converting enzyme/a disintegrin and metalloprotease-17 mediates mechanotransduction in murine tracheal epithelial cells.
Shiomi T; Tschumperlin DJ; Park JA; Sunnarborg SW; Horiuchi K; Blobel CP; Drazen JM
Am J Respir Cell Mol Biol; 2011 Aug; 45(2):376-85. PubMed ID: 21097655
[TBL] [Abstract][Full Text] [Related]
13. PDIA6 regulation of ADAM17 shedding activity and EGFR-mediated migration and invasion of glioblastoma cells.
Kim TW; Ryu HH; Li SY; Li CH; Lim SH; Jang WY; Jung S
J Neurosurg; 2017 Jun; 126(6):1829-1838. PubMed ID: 27540907
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia.
Szalad A; Katakowski M; Zheng X; Jiang F; Chopp M
J Exp Clin Cancer Res; 2009 Sep; 28(1):129. PubMed ID: 19772640
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication.
Argast GM; Campbell JS; Brooling JT; Fausto N
J Biol Chem; 2004 Aug; 279(33):34530-6. PubMed ID: 15199050
[TBL] [Abstract][Full Text] [Related]
16. Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands.
Nakagawa M; Nabeshima K; Asano S; Hamasaki M; Uesugi N; Tani H; Yamashita Y; Iwasaki H
Cancer Sci; 2009 Apr; 100(4):654-62. PubMed ID: 19298600
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.
Guo Y; He X; Zhang M; Qu Y; Gu C; Ren M; Wang H; Ning W; Li J; Yu C; Zhang H
J Neurooncol; 2020 Apr; 147(2):327-337. PubMed ID: 32170633
[TBL] [Abstract][Full Text] [Related]
18. Hormone-induced expression of tumor necrosis factor alpha-converting enzyme/A disintegrin and metalloprotease-17 impacts porcine cumulus cell oocyte complex expansion and meiotic maturation via ligand activation of the epidermal growth factor receptor.
Yamashita Y; Kawashima I; Yanai Y; Nishibori M; Richards JS; Shimada M
Endocrinology; 2007 Dec; 148(12):6164-75. PubMed ID: 17901238
[TBL] [Abstract][Full Text] [Related]
19. iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling.
Li X; Maretzky T; Weskamp G; Monette S; Qing X; Issuree PD; Crawford HC; McIlwain DR; Mak TW; Salmon JE; Blobel CP
Proc Natl Acad Sci U S A; 2015 May; 112(19):6080-5. PubMed ID: 25918388
[TBL] [Abstract][Full Text] [Related]
20. Caveolin-1 is required for TGF-β-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17.
Moreno-Càceres J; Caja L; Mainez J; Mayoral R; Martín-Sanz P; Moreno-Vicente R; Del Pozo MÁ; Dooley S; Egea G; Fabregat I
Cell Death Dis; 2014 Jul; 5(7):e1326. PubMed ID: 25032849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
